Findings Reported From DEFINE-FLOW Study of Deferral of PCI in FFR-Abnormal Lesions With Preserved Coronary Flow Reserve
October 16, 2020—A new observational study of deferred lesions following combined fractional flow reserve (FFR) and coronary flow reserve (CFR) assessments found that untreated vessels with abnormal FFR but intact CFR do not have noninferior outcomes compared to those with an FFR > 0.8 and a CFR ≥ 2.0 when treated medically.
Physiology-guided PCI Optimization Strategy Evaluated in TARGET FFR Study
October 16, 2020—Results from the randomized controlled TARGET FFR trial showed that while a physiology-guided percutaneous coronary intervention (PCI) optimization strategy did not achieve a significant increase in the proportion of patients with final FFR ≥ 0.9, it reduced the proportion of patients with a residual FFR ≤ 0.8 after PCI.
FORECAST Trial Investigates Cost and Clinical Advantage of FFR Derived From CT
October 16, 2020 –The use of fractional flow reserve management derived from computed tomography (FFRCT) did not significantly reduce costs but did reduce the use of invasive coronary angiography (ICA) in the FORECAST randomized clinical trial.
1-Year DEFINE PCI Data Presented for Philips' iFR-Guided Interventions
October 15, 2020—Royal Philips announced that the 1-year results of the DEFINE PCI study were presented at TCT Connect, the 32nd annual Transcatheter Cardiovascular Therapeutics scientific symposium of the Cardiovascular Research Foundation held online October 14-18, 2020.
Pilot Randomized PROSPECT ABSORB Trial Evaluates Safety of PCI of Nonflow-Limiting Vulnerable Plaques
October 14, 2020—New data from PROSPECT ABSORB, a pilot randomized trial of percutaneous coronary intervention (PCI) of nonflow-limiting vulnerable plaques in native coronary arteries, found that PCI was safe, substantially enlarged follow-up lumen areas, and was associated with favorable long-term clinical outcomes. The PROSPECT ABSORB study was an investigator-sponsored, multicenter, single-blinded, active-treatment-controlled randomized trial that was embedded into the PROSPECT II natural history study.
Combined FFR and OCT Imaging Studied to Identify High-Risk Lesions in Patients With Diabetes
October 14, 2020—The COMBINE (OCT-FFR) study found that the use of fractional flow reserve (FFR) combined with optical coherence tomography (OCT) imaging can help improve the accuracy of high-risk lesion identification in patients with diabetes.
PROSPECT II Shows Benefit of NIRS-IVUS Imaging to Identify Vulnerable Plaque
October 14, 2020—New data from the PROSPECT II study shows that near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS) intracoronary imaging can help identify angiographically nonobstructive lesions with high-risk characteristics for future adverse cardiac outcomes.
SCCT Announces Report Recommending CTA-First Approach for Stable CAD
September 8, 2020—The Society of Cardiovascular Computed Tomography (SCCT) announced the publication of a report, “Current Evidence and Recommendations for Coronary CTA First in Evaluation of Stable Coronary Artery Disease,” that outlines the benefits of coronary CTA as a first-use strategy in treating stable coronary artery disease (CAD).
GE Healthcare to Distribute Osprey Medical’s Contrast-Reduction Technology in Europe and Other Regions
July 30, 2020—GE Healthcare and Osprey Medical Inc. announced a strategic alliance under which GE Healthcare will exclusively distribute Osprey’s product portfolio in Europe, Russia, the Middle East, Africa, Central Asia, and Turkey.
Canon Medical Introduces New Configuration of Aquilion One/Genesis Edition Cardiac CT Solution
July 17, 2020—Canon Medical Systems USA, Inc. announced the introduction of a new configuration of the Aquilion One/Genesis Edition, an artificial intelligence–powered wide-area CT system for structural and coronary imaging.
Abbott’s LightLab Initiative Shows OCT Imaging Changes Coronary Treatment Decisions
June 26, 2020—Abbott announced that the first data reported from the company’s LightLab Initiative showed that optical coherence tomography (OCT) imaging significantly changes how physicians decide to treat a vessel (compared to traditional angiography) by providing physicians improved visualization within a patient’s blood vessels.
CHOW NOW Study Compares Eating Versus Fasting Before Cardiac Catheterizations
May 14, 2020—The Society for Cardiovascular Angiography and Interventions (SCAI) announced findings from the single-center, randomized CHOW NOW study that aimed to compare the safety and clinical outcomes of a nonfasting (NF) strategy as compared with the current standard fasting (SF) protocol.
OCT Imaging Studied to Predict FFR Values in Coronary Lesions
May 14, 2020—The Society for Cardiovascular Angiography and Interventions (SCAI) announced findings from a study that sought to evaluate whether optical coherence tomography (OCT) parameters may predict fractional flow reserve (FFR) values and assess if OCT parameters may predict clinical outcome in patients with negative FFR.
US Device Guide
This Device Guides offers a searchable, comprehensive listing of the available interventional cardiology devices in the United States.
European Device Guide
This Device Guides offers a searchable, comprehensive listing of the available interventional cardiology devices in Europe.